Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Year: 2020
Type: article
Abstract: Since its first detection in China in late 2019 the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious disease COVID-19 continue to have a major impact on global healthcare and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria.
Source: European Journal of Cancer
Authors: Nicola Giesen, Rosanne Sprute, Maria Rüthrich, Yascha Khodamoradi, Sibylle C. Mellinghoff, Gernot Beutel, Catherina Lueck, Michael Koldehoff, Marcus Hentrich, Michael Sandherr, Michael von Bergwelt-Baildon, Hans-Heinrich Wolf, Hans H. Hirsch, Bernhard Wörmann, Oliver A. Cornely, Philipp Köhler, Enrico Schalk, Marie von Lilienfeld-Toal
Institutions: University Hospital Heidelberg, University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Jena University Hospital, Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI), Goethe University Frankfurt, Medizinische Hochschule Hannover, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Essen University Hospital, University of Duisburg-Essen, German Red Cross, LMU Klinikum, Ludwig-Maximilians-Universität München, Südharz Klinikum, University of Basel, University Hospital of Basel, Charité – Universitätsmedizin Berlin, Otto-von-Guericke-Universität Magdeburg
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,800
Funders: Amgen, Pfizer, Novartis, Roche, Sanofi, Celgene, Medpace, Deutsches Zentrum für Infektionsforschung, Cidara Therapeutics, Jazz Pharmaceuticals, Mylan, Amplyx, Nabriva Therapeutics, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Shionogi, Deutsche Krebshilfe, Universität zu Köln, Medac, Octapharma, Da Volterra, Chugai Pharmaceutical, Roche Diagnostics, Janssen Biotech, F2G, MSD Sharp and Dohme
OpenAlex ID: W3087138342